HHS Peptide Policy 2026: What the Six-Peptide Announcement Means

The Federal Register notice announces the availability of a draft enforcement-discretion policy. In plain language, HHS describes circumstances in which it does not intend to take specified enforcement action over certain peptide compounding while the 503A bulks list develops through rulemaking. That is a decision about enforcement priorities, with conditions. It is not a finding that a finished medicine is safe and effective.

The distinction changes what a headline can reasonably promise. A person reading “six peptides approved” might expect evaluated benefits, an approved label, and a treatment ready at any pharmacy. This announcement establishes none of those expectations. Read the current policy and its appendices together.

The HHS policy identifies BPC-157 acetate, TB-500 acetate, Epitalon acetate, Semax free base, KPV acetate, and MOTS-c acetate. Chemical form is part of that list. A similar trade name, another salt, a blend, or a research product should not be assumed to fit because its label includes one familiar peptide name.

Appendix A names the substances; Appendix B provides the identities and route limits. KPV is limited to topical and oral forms, while Semax is limited to intranasal use. The draft also specifies single-API preparations, so it should not be used to promote blends.

These entries remain subject to all draft conditions. For oral preparations, the compounder would need documentation of adequate human oral bioavailability for the exact formulation. A listed route is not a dosing instruction or permission to bypass the other safeguards.

This is also a bounded list. It does not add every peptide discussed online or turn a broader peptide catalog into approved treatments. The earlier FDA committee meeting considered seven peptide groups, including emideltide, also called DSIP. A meeting agenda and the later policy list are different documents with different purposes.

The policy concerns specified compounding by state-licensed pharmacies, federal facilities, or licensed physicians under section 503A. It is not a general invitation for any online seller to supply injectable products. It also does not erase the other requirements governing compounding, prescribing, or professional practice.

For a patient, the useful questions are specific: what exact substance and preparation is being considered, who is prescribing it, which pharmacy is preparing it, and what policy conditions apply? A clinician still needs to assess the health problem, alternatives, uncertainties, and reasons a proposed treatment might be inappropriate. News coverage cannot answer those questions for an individual.

No. The notice explicitly says compounded drugs are not FDA-approved and FDA does not review their safety, effectiveness, or quality before marketing. The policy also says HHS may revisit its approach if safety signals or quality problems arise. An enforcement decision should therefore not be repackaged as proof of benefit.

Nor does discussion of an intended use establish an approved indication. The FDA committee evaluated specific proposed uses, including ulcerative colitis for BPC-157 and insomnia for Epitalon. Those were questions for review, not permission to advertise that the peptides treat those conditions. Evidence needs to be assessed separately for the precise product and health outcome.

The public-inspection notice schedules publication for October 30, 2026 and describes a comment period lasting two weeks after publication. As of this article’s October 28 update, that publication is still scheduled. The notice calls the policy draft and nonbinding; avoid assuming a permanent final rule or inventing an effective date.

Check the HHS document for updates before relying on an earlier article or screenshot. For the process behind the headlines, see our policy timeline and approval-versus-discretion explainer. If you are considering care, bring your health goals and current medicines to a clinician. This article does not confirm that Peppy offers any of the six substances.